Publication

Article

Pharmacy Times

August 2012 Pain Awareness
Volume78
Issue 8

Evolving Therapeutic Strategies in Cancer Therapy-Induced Bone Loss: The Pharmacist's Role in Minimizing Fractures

This activity is supported by an educational donation provided by Amgen.

Evolving Therapeutic Strategies in Cancer Therapy—Induced Bone Loss: The Pharmacist's Role in Minimizing Fractures

Rick Miller, PharmD, BCPS, BCOP

Allegheny General HospitalDepartment of Pharmacy ServicesClinical Adjunct FacultyUniversity of PittsburghDuquesne UniversityPittsburgh, PA

Gerard Mascara, PharmD

PGY2 Hematology/Oncology PharmacyResidentAllegheny General HospitalPittsburgh, PA

Rick Miller, PharmD, BCPS, BCOP, and Gerard Mascara, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.

Pharmacy Times Office of Continuing Professional Education Planning Staff

Judy V. Lum, MPA, Ann C. Lichti, CCMEP, and Elena Beyzarov, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.

Pharmacy Times Editorial Staff

Jennifer Whartenby and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.

The peer reviewer of this activity has no relevant financial relationships with commercial interests to disclose related to this activity.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Examine the physiology and biochemical mechanisms associated with general bone health, normal bone loss, and bone loss due to secondary causes, particularly cancer therapy—induced bone loss (CTIBL).
  • Identify patients at risk for CTIBL and subsequent fractures, and recommend bone mineral density testing and/or physician referral in an effort to minimize burden of fractures.
  • Recommend appropriate nonpharmacologic and pharmacologic interventions for management of CTIBL and ensure follow-up monitoring.
  • Formulate counseling strategies regarding prevention and management of CITBL including lifestyle modification and medication adherence.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: August 10, 2012

Expiration date: August 10, 2014

Estimated time to complete activity: 2 hours

Fee: This lesson is free online

Click here to view this activity.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com